Completed PHASE3 INTERVENTIONAL 3-arm NCT04942860

The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo (EVRAM)

Sponsor: Nicolaus Copernicus University

Interventions 0.5% Methotrexate gel 1% Methotrexate gel

Updated 5 times since 2021 Last updated: Sep 8, 2023 Started: Oct 1, 2019 Primary completion: Jun 1, 2023 Completion: Aug 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non-segmental Vitiligo and is currently completed. Nicolaus Copernicus University leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2023 — Jul 2024 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jul 2023 — Oct 2023 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Sep 2021 — Jul 2023 [monthly]

Recruiting PHASE3

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nicolaus Copernicus University

Data source: Nicolaus Copernicus University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bydgoszcz, Poland